Seneca Therapeutics Announces Acceptance of Late Breaking SVV-001 Abstract to American Association for Cancer Research Annual Meeting April 10-15, 2021

Seneca Therapeutics Announces Acceptance of Late Breaking SVV-001 Abstract to American Association for Cancer Research Annual Meeting April 10-15, 2021




Seneca Therapeutics Announces Acceptance of Late Breaking SVV-001 Abstract to American Association for Cancer Research Annual Meeting April 10-15, 2021

PHILADELPHIA–(BUSINESS WIRE)–Seneca Therapeutics, Inc. (“STI”), a clinical-stage biopharmaceutical company dedicated to the development of targeted oncolytic immunotherapeutics based on Seneca Valley Virus (SVV-001) announced today the acceptance of a late breaking SVV-001 abstract to the American Association for Cancer Research annual meeting. The study titled “Oncolytic Seneca Valley Virus (SVV) overcomes resistance to checkpoint inhibitor therapies in neuroendocrine and melanoma murine models expressing the receptor for SVV”, was accepted for the e poster session during the meeting. The details of the abstract viewing are below:

Abstract Control Number: 5232

Title: Oncolytic Seneca Valley Virus (SVV) overcomes resistance to checkpoint inhibitor therapies in neuroendocrine and melanoma murine models expressing the receptor for SVV

Session Type: E-Poster Session

Session Category: Clinical Research (Excluding Trials)

Session Title: Combination Immunotherapies

About Seneca Therapeutics

Seneca Therapeutics was founded by Dr. Paul Hallenbeck to develop SVV-001 related products. Seneca Therapeutics is also developing armed versions of SVV-001 to selectively express gene product(s) that are inserted into the genome of SVV-001 and create additional anti-tumor effects.

Forward-Looking Statements

This press release contains “forward-looking statements” concerning the development of Seneca Therapeutics products, the potential benefits and attributes of those products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Seneca Therapeutics undertakes no obligation to update any forward-looking statements for any reason.

Contacts

Paul Hallenbeck

phallenbeck@senecatherapeutics.com

James Hussey

jhussey@senecatherapeutics.com

www.senecatherapeutics.com